Atria Wealth Solutions Inc. Raises Stock Holdings in Abbott Laboratories (NYSE:ABT)

Atria Wealth Solutions Inc. lifted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 5.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 71,314 shares of the healthcare product maker’s stock after purchasing an additional 3,670 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Abbott Laboratories were worth $7,849,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of ABT. Wellington Management Group LLP grew its stake in Abbott Laboratories by 4.3% in the third quarter. Wellington Management Group LLP now owns 31,208,711 shares of the healthcare product maker’s stock worth $3,022,564,000 after purchasing an additional 1,298,219 shares during the period. Northern Trust Corp lifted its holdings in Abbott Laboratories by 1.5% in the third quarter. Northern Trust Corp now owns 23,016,235 shares of the healthcare product maker’s stock valued at $2,229,122,000 after acquiring an additional 343,559 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Abbott Laboratories by 0.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 12,153,877 shares of the healthcare product maker’s stock valued at $1,164,611,000 after acquiring an additional 32,157 shares during the period. Flossbach Von Storch AG raised its stake in shares of Abbott Laboratories by 1.5% in the fourth quarter. Flossbach Von Storch AG now owns 9,149,611 shares of the healthcare product maker’s stock worth $1,007,098,000 after buying an additional 135,821 shares during the period. Finally, Invesco Ltd. raised its stake in shares of Abbott Laboratories by 0.4% in the third quarter. Invesco Ltd. now owns 5,949,700 shares of the healthcare product maker’s stock worth $576,228,000 after buying an additional 20,851 shares during the period. Institutional investors own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Barclays decreased their price objective on Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating on the stock in a research note on Monday. Evercore ISI increased their target price on Abbott Laboratories from $120.00 to $125.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. Raymond James restated a “buy” rating and set a $124.00 price target on shares of Abbott Laboratories in a report on Wednesday. Royal Bank of Canada lowered their price objective on Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating for the company in a research note on Thursday, April 18th. Finally, Citigroup raised their price objective on Abbott Laboratories from $126.00 to $128.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $121.50.

Abbott Laboratories Trading Up 0.0 %

ABT traded up $0.01 during mid-day trading on Friday, hitting $106.87. 181,153 shares of the stock were exchanged, compared to its average volume of 5,617,918. The firm’s fifty day moving average is $113.77 and its two-hundred day moving average is $107.96. Abbott Laboratories has a 1-year low of $89.67 and a 1-year high of $121.64. The company has a current ratio of 1.64, a quick ratio of 1.16 and a debt-to-equity ratio of 0.35. The company has a market cap of $185.44 billion, a PE ratio of 33.22, a PEG ratio of 2.57 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Wednesday, April 17th. The healthcare product maker reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.02. Abbott Laboratories had a return on equity of 20.32% and a net margin of 13.96%. The firm had revenue of $9.96 billion for the quarter, compared to analyst estimates of $9.88 billion. During the same quarter in the prior year, the company earned $1.03 EPS. Abbott Laboratories’s revenue was up 2.2% on a year-over-year basis. Equities analysts forecast that Abbott Laboratories will post 4.62 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Monday, April 15th will be issued a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, April 12th. This represents a $2.20 annualized dividend and a yield of 2.06%. Abbott Laboratories’s dividend payout ratio (DPR) is 68.54%.

Insiders Place Their Bets

In other Abbott Laboratories news, EVP Andrea F. Wainer sold 12,500 shares of the company’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the sale, the executive vice president now owns 78,704 shares in the company, valued at approximately $9,444,480. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, EVP Daniel Gesua Sive Salvadori sold 963 shares of the stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $118.50, for a total value of $114,115.50. Following the transaction, the executive vice president now owns 125,697 shares in the company, valued at approximately $14,895,094.50. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Andrea F. Wainer sold 12,500 shares of the stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $120.00, for a total value of $1,500,000.00. Following the completion of the transaction, the executive vice president now owns 78,704 shares in the company, valued at approximately $9,444,480. The disclosure for this sale can be found here. Insiders have sold a total of 56,435 shares of company stock worth $6,451,298 in the last quarter. 1.10% of the stock is owned by company insiders.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.